Metronomic chemotherapy of paclitaxel plus cisplatin in patients with metastatic breast cancer: a target trial emulation study.

ABSTRACT:

Background

As metastasis drives the majority of breast cancer-related deaths, improving outcomes for metastatic breast cancer (MBC) remains a crucial challenge. Observational studies using target trial emulation are increasingly applied to estimate treatment effects, providing insights when randomized trials are not viable.

Objectives

To estimate the effect of progression-free survival (PFS) of metronomic chemotherapy of weekly paclitaxel plus cisplatin (DP) compared with treatment of the physician's choice (TPC) for MBC.

Design

This analysis was designed as a retrospective cohort study according to STROBE criteria.

Methods

This retrospective cohort study compared metronomic chemotherapy of weekly DP versus TPC in MBC. The DP regimen included paclitaxel (80 mg/

SUBMITTER: Li Y 

PROVIDER: S-EPMC12536206 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature